Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
{{output}}
Accurate assessment of human epidermal growth factor receptor 2 (HER2) status is crucial for effective breast cancer treatment planning and improved patient outcomes. Traditional needle biopsies, limited in tissue sampling, often lead to inaccurate assessments... ...
